linjc16/ctgov huggingface dataset:
Accuracy of 3DPrinted Windowed Bracket- Positioning Guide Compared To Thermoformed Indirect Bonding Tray

Study Overview
=================
Brief Summary
-----------------
this study was aimed to evaluate of accuracy of 3DPrinted windowed Bracket- Positioning Guide in compare to Thermoformed Transfer Tray For Orthodontic Indirect Bonding

Official Title
-----------------
Evaluation of Accuracy of 3DPrinted Windowed Bracket- Positioning Guide Compared To Thermoformed Transfer Tray For Orthodontic Indirect Bonding A Randomized Controlled Trial

Conditions
-----------------
Inaccurate Transfer and Bond Failure of Conventional Indirect Bonding Tray, Accuracy of Bracket Transfer and Bond Failure Rate of Digitally Printed Transfer Tray With Windows and Conventional Thermoformed Transfer Tray

Intervention / Treatment
-----------------
* Device: 3DPrinted Windowed Bracket- Positioning tray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: above 13 years. Complete set of permanent teeth including second molar. No sex predilection. Class I Mild to moderate crowding (4-6 mm). Exclusion Criteria: Surface enamel defect that compromise bonding No or poor patient's compliance. Psychological problems. Pathology at the site of intervention. Insufficient crown height that contradicts bonding of brackets. Labial and buccal Restorations. Poor oral hygiene. Severely rotated teeth

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: window bracket positioning tray<br> | Device: 3DPrinted Windowed Bracket- Positioning tray<br>* 3 D printed tray with windows for accurate positioning of brackets<br>|
| No Intervention: conventional indirect boning tray<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| accuracy of 3D printed transfer tray with windows& conventional thermoformed transfer tray | using digital measurements on 3 shape software in mm degrees | immediate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| chairside time | digital stopwatch in seconds | immediate | 
| immediate bond failure | counting after bonding number of brackets or tubes failed immediately | immediate |
Drainage or Pericardiocentesis (DROP) Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention

Study Overview
=================
Brief Summary
-----------------
The DROP study is a prospective, multi center, randomized, open-label trial to test the efficacy and safety of extended catheter pericardial drainage in patients with non-malignant pericardial effusions.

Detailed Description
-----------------
The trial will compared the efficacy and safety of pericardiocentesis alone compared with extended pericardial catheter drainage for the prevention of recurrent effusions in patients with non-malignant pericardial effusions requiring intervention.

Official Title
-----------------
Drainage or Pericardiocentesis Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention.

Conditions
-----------------
Pericardial Effusion

Intervention / Treatment
-----------------
* Procedure: Extended pericardial drainage by catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients pericardial effusion requiring pericardiocentesis non-malignant etiology Exclusion Criteria: known neoplastic etiology known bacterial etiology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Pericardiocentesis<br>Pericardial fluid drained by simple echo-guided pericardiocentesis | |
| Active Comparator: Extended pericardial drainage<br>Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml | Procedure: Extended pericardial drainage by catheter<br>* Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent pericardial effusion |  | 12 months | 
| Need for repeated pericardiocentesis |  | 12 months | 
| Need for cardiac surgery |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital stay |  | 12 months | 
| Disease-related hospitalization |  | 12 months | 
| Overall mortality |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pericardial effusion, cardiac tamponade, pericardiocentesis, pericardial drainage, prevention
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice. A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey will be conducted at month 0, 3, 6 using ACTS/TSQM. This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.

Official Title
-----------------
Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)

Conditions
-----------------
Non-valvular Atrial Fibrillation (NVAF)

Intervention / Treatment
-----------------
* Drug: Rivaroxaban (Xarelto_ BAY59-7939)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated by Warfarin for their atrial fibrillation for at least two months at the time of the study initiation. Rivaroxaban naïve patients Patients 20 years old or older. Patients who agree to sign the inform consent Exclusion Criteria: Patients who are contraindicated by product label

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Patients treated with Xarelto under practical manner for SPAF. | Drug: Rivaroxaban (Xarelto_ BAY59-7939)<br>* Patients treated with Xarelto under practical manner for SPAF.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of treatment satisfaction (Evaluated through ACTS and TSQM questionnaires) |  | Up to 6 months | 
| Incidence of ADRs and serious AEs (especially for hemorrhagic events, and liver disfunction with increase of liver-function-relating enzymes including bilirubin) |  | Up to 6 months | 
| Incidence of events of stroke |  | Up to 6 months | 
| Incidence of events of non-central nervous system embolism |  | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Xarelto, SPAF, QOL
Study of Difluprednate in the Treatment of Uveitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.

Conditions
-----------------
Uveitis

Intervention / Treatment
-----------------
* Drug: Difluprednate
* Drug: Prednisolone Acetate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of endogenous anterior uveitis in at least 1 eye Exclusion Criteria: Presence of intermediate uveitis, posterior uveitis or panuveitis Corneal abrasion Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease Allergy to similar drugs, such as other corticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Difluprednate|nan|
|Drug: Prednisolone Acetate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Tractography Pilot Study Leipzig

Study Overview
=================
Brief Summary
-----------------
In this pilot study participants will undergo routine magnetic resonance imaging and routine neurosurgical care. By prospectively collecting data from both MRI and patient records we want to investigate biomarkers derived from tractography and diffusion tensor imaging to predict rehabilitation potential.

Detailed Description
-----------------
Patients will undergo MRI before and after surgery with DTI. With CSD-tractography, fiber bundles and their volumes will be identified. By measuring fractional anisotropy (FA) within these volumes, a correlation with clinical outcome and recovery will be tested. Also, FA frequency distributions will be used to describe white matter integrity and to thereby improve future tractography algorithms. Fiber bundles of interest will be the arcuate fascicle (AF), the corticospinal tract (CST), frontal aslant tract (FAT), the inferior fronto-occipital fascicle (IFOF), the inferior longitudinal fascicle (ILF) and the uncinate fascicle (UF).

Official Title
-----------------
Pilot Study for Establishing Perioperative Tractography at Leipzig University Neurosurgery

Conditions
-----------------
Intracranial Neoplasm

Intervention / Treatment
-----------------
* Other: routine MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intracranial lesion elective neurosurgical procedure Exclusion Criteria: MRI not applicable cerebral ischemia during study period pregnancy during study period encephalitis during study period spontaneous intracerebral hemorrhage during study period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: routine MRI|MRI with routine DTI sequence|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological Performance | Neurological Performance Score (NPS) | three months |
Computer Vision Syndrome Prevalence Among University Students

Study Overview
=================
Brief Summary
-----------------
CVS-F3 questionnaire will be used as an instrument to survey CVS prevalence and severity among medical students

Detailed Description
-----------------
CVS-F3 is a valid questionnaire that includes 26 questions to be responded by the medical students to detect CVS complains and possible complications. The questionnaire includes questions regarding potential ocular, extra-ocular, musclo-skeletal and neuro-psychatric complains caused by CVS. Complete statistical analysis of the survey data will be done using univariate and multivariate logistic and linear regression analysis.

Official Title
-----------------
Prevalence and Severity of Computer Vision Syndrome Among Medical Students

Conditions
-----------------
Computer Vision Syndrome

Intervention / Treatment
-----------------
* Behavioral: CVS GROUP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: university students studying medicine Exclusion Criteria: ocular surgery amblyopia anisometropia strabismus DM hypertension
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of CVS | will be reorted in form of percentage (%) of students with CVS | 1 month | 
| Visual acuity | measurement of visual acuity using distance visual charts in logMAR measurements | 1 month | 
| Refraction | measurement of refractive power in diopters | 1 month | 
| Schirmer test | measurement of tear volume production with Schirmer test in mm unit measurements | 1 month | 
| Tear Break Up Time (TBUT) | measurement of tear film stability with TBUT in seconds time unit measurements | 1 month | 
| mfERG examinations | mfERG will be performed for the students to document the effect of CVS on retina | 6 months |
Acute Effect of Massage and Exercise on Muscle Tenderness

Study Overview
=================
Brief Summary
-----------------
Many people experience pain, tenderness and soreness of joint and muscles, both in sport and working life. Pain killers can provide acute relief of pain, but may not be a feasible solution for all people. Here the investigators examine the acute effect of massage and exercise on induced muscle tenderness (delayed onset muscular soreness).

Official Title
-----------------
Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace

Conditions
-----------------
Musculoskeletal Disorders

Intervention / Treatment
-----------------
* Behavioral: Exercise
* Other: Massage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: working age adults Exclusion Criteria: blood pressure above 160/100 disease of the cervical spine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Massage<br>massage will be provided for 10 minutes at the left or right trapezius (randomized) | Other: Massage<br>* massage will be provided for 10 minutes at the left or right trapezius (randomized)<br>|
| Experimental: Exercise<br>exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized) | Behavioral: Exercise<br>* Exercise will be performed for 10 minutes at the left or right trapezius (randomized)<br>|
| No Intervention: Control<br>control shoulder (randomized) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceived tenderness of the trapezius muscle on a numerical rating scale of 0-10 | Perceived tenderness where 0 is no tenderness and 10 is worst imaginable tenderness | change from before to after the acute intervention (average of 0, 10, 20 and 60 min after the intervention) | 
| Pressure pain threshold of the trapezius muscle |  | change from before to after the acute intervention (average of 0, 10, 20 and 60 min after the intervention) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DOMS
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.

Detailed Description
-----------------
The purpose of this study is to determine which of two delivery methods of PTH is preferred by patients after 14 days of use for each. Patient preference will be determined by means of patient questionnaires at the end of each treatment period and a final questionnaire after both treatment periods are complete. Adverse events will also be collected.

Official Title
-----------------
An Open-label Crossover Study to Determine the Patient Preference Between ZP-PTH Patches and Forteo Pens After Daily Treatment for 14 Days in Women 55-85 Years of Age

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Drug: ZP-PTH
* Drug: FORTEO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal with prior diagnosis of osteoporosis Exclusion Criteria: Significant health issue previous use of teriparatide History of Paget's disease

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ZP-PTH Patch<br>Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment | Drug: ZP-PTH<br>* Patch applied daily for 30 minutes, 14 days<br>* Other names: teriparatide;|
| Active Comparator: FORTEO(R) Pen<br>Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment. | Drug: FORTEO<br>* Subcutaneous injection administration daily for 14 days<br>* Other names: teriparatide;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Preference | The fraction of subjects expressing an overall preference for each treatment based on a 4 point scale | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | incidence of adverse events | 28 days |
Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

Study Overview
=================
Brief Summary
-----------------
This study will assess the distribution of topical gel in the human vagina, using enhanced MRI techniques. The number and size of uncovered areas will be studied, and the upper genital tract will be examined for the presence of topical gel using MRI.

Detailed Description
-----------------
This study will assess the distribution of topical gel in the human vagina, using enhanced MRI techniques. The number and size of uncovered areas will be studied, and the upper genital tract will be examined for the presence of topical gel using MRI. MRIs will be performed with both a standard pelvic coil and an enhanced resolution endo-rectal coil in order to obtain maximal resolution. MRI images will be acquired before and after simulated coitus.

Official Title
-----------------
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Drug: HEC placebo gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 45 year old women not pregnant willingness to use effective method of contraception regular menstrual cycle normal Pap test result Exclusion Criteria: abnormal pelvic exam pregnant or breastfeeding claustrophobia or other MRI contraindications hypertension, hemolytic anemia,latex allergy history of hemorrhoids or irritable bowel syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: HEC placebo gel|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Number and size of bare spots, before and after simulated coitus. |  |  | 
| 2. Number of women with migration of gel into the endocervical canal and/or endometrial canal before and after simulated coitus. |  |  |